MicroRNA-126-3p as a predictive biomarker for patients with primary biliary cholangitis refractory to ursodeoxycholic acid

Table 2 Preliminary screening of differentially expressed microRNAs in the drug-sensitive and drug-resistant groups before ursodeoxycholic acid treatment

Groups	MiRNAs	MiR_sequencing		Log2FC	FC	P value	Expression level
Differential expression in DS group before and after treatment	Hsa-miR-126-3p	TCGTACCGTGAGTAATAATGC	Up	0.686818109	1.61	0.002	High
	Hsa-miR-223-3p	TGTCAGTTTGTCAAATACCCCAA	Up	0.36848971	1.29	0.008	High
	Hsa-miR-22-5p	AGTTCTTCAGTGGCAAGCTTTA	Up	0.348412695	1.27	0	Middle
	Hsa-miR-556-5p	GATGAGCTCATTGTAATATGA	Up	0.587162181	1.5	0.008	Middle
	Hsa-miR-130a-3p	CAGTGCAATGTTAAAAGGGCAT	Up	0.5645536	1.48	0.009	Middle
	Hsa-miR-10a-5p	TACCCTGTAGATCCGAATTTGT	Down	-0.50035024	0.71	0.001	Middle
	Hsa-miR-7706	TGAAGCGCCTGTGCTCTGCCGAG	Down	-1.27927924	0.41	0.007	Middle
Stable expression in DS group before and after treatment	Hsa-miR-219a-5p	TGATTGTCCAAACGCAATTCTCG	Up	2.968566339	7.83	0.003	Middle
	Hsa-miR-3909	TGTCCTCTAGGGCCTGCAGTCT	Down	-1.39892689	0.38	0.012	Middle
	Hsa-miR-6513-3p	TCAAGTGTCATCTGTCCCTAGA	Down	-0.95445711	0.52	0.035	Middle
	Hsa-miR-146b-3p	GCCCTGTGGACTCAGTTCTGGT	Down	-0.48419167	0.71	0.012	Middle

MiRNAs: MicroRNAs; FC: Fold change; DS: Drug-sensitive.